01Jun 2021
Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study

Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study

The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1‐84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone...

  • #endo-diabetology

Like

Save

Share